問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Nephrology

更新時間:2023-09-19

鍾牧圻
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

9Cases

2020-04-01 - 2023-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Not yet recruiting9Sites

Terminated6Sites

2022-10-01 - 2024-03-11

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting9Sites

2023-11-10 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2023-11-01 - 2027-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2022-01-05 - 2029-11-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2024-12-30 - 2031-06-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-01-01 - 2018-12-31

Phase IV

A Long-Term, Open-Label, Prospective Observational Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects with End Stage Renal Disease (ESRD) on Dialysis.
  • Condition/Disease

    Hyperphosphatemia/End Stage Renal Disease (ESRD)

  • Test Drug

    NEPHOXIL®

Participate Sites
9Sites

Terminated9Sites

2019-03-26 - 2023-02-06

Phase III

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
  • Condition/Disease

    Immunoglobulin A nephropathy

  • Test Drug

    Nefecon™

Participate Sites
3Sites

Recruiting3Sites